

OPEN ACCESS

APPROVED BY

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE

Frontiers Production Office,

production.office@frontiersin.org

RECEIVED 27 April 2023 ACCEPTED 27 April 2023 PUBLISHED 05 May 2023

CITATION

Frontiers Production Office (2023), Erratum: Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Front. Pharmacol. 14:1213155. doi: 10.3389/fphar.2023.1213155

COPYRIGHT

© 2023 and Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).

The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Erratum: Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

benzylisoquinoline alkaloids, stylopine, MG-63, osteosarcoma, VEGFR2

An Erratum on

Stylopine: A potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

by Velayutham NK, Thamaraikani T, Wahab S, Khalid M, Ramachawolran G, Abullais SS, Wong LS, Sekar M, Gan SH, Ebenezer AJ, Ravikumar M, Subramaniyan V, Mat Rani NNI, Wu YS and Jeyabalan S (2023). Front. Pharmacol. 14:1150270. doi: 10.3389/fphar.2023.1150270

Due to a production error, there was an error in affiliation 4. Instead of "Department of Foundation, Georgetown, Pulau Pinang, Malaysia," it should be "Department of Foundation, RCSI & UCD Malaysia Campus, George Town, Pulau Pinang, Malaysia."

The publisher apologizes for this mistake. The original version of this article has been updated.